TY -的T1 -包含bedaquiline方案和delamanid相比,耐药结核病患者bedaquiline JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01181 -2019欧元六世- 55 - 1 SP - 1901181 AU Olayanju Olatunde盟——提出Aliasgar AU - Limberis,杰森盟——DhedaKeertan Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/55/1/1901181.abstract N2 - delamanid和bedaquiline联合用于耐药结核病(DR-TB)方案的数据有限。无法获得包括艾滋病毒感染者在内的前瞻性长期预后数据。在2014年至2018年期间，我们对122名具有耐药结核和预后不良特征的南非患者(52.5%的艾滋病毒感染者)进行了前瞻性随访。我们对接受bedaquiline-based方案(n=82)和接受bedaquiline-delamanid联合方案(n=40)的患者的结局和安全性进行了研究。6个月培养转化率无显著差异(92.5% vs 81.8%;P =0.26)和18个月的有利结局率(63.4% vs 67.5%;P =0.66)，尽管后者的耐药率更高(3.7%对至少5种药物耐药率为22.5%;p=0.001)和更高的治疗前失败率(治疗前耐多药结核病治疗失败的12.2%对52.5%;术中,0.001)。虽然使用Fridericia公式校正的QT间期延长比例在联合组中更高(与基线相比60 ms (p=0.001)或治疗期间450 ms (p=0.001)，但两组均未出现症状病例或药物停药。 Results were similar in HIV-infected patients.A bedaquiline–delamanid combination regimen showed comparable long-term safety compared to a bedaquiline-based regimen in patients with DR-TB, irrespective of HIV status. These data inform regimen selection in patients with DR-TB from TB-endemic settings.A bedaquiline–delamanid combination regimen in drug-resistant tuberculosis patients with poor prognostic factors showed comparable efficacy and safety to those in a bedaquiline-based regimen http://bit.ly/32j7Fyo ER -